Global Peptide-based Cancer Therapeutics Market Size to Exceed USD 71.5 Billion by 2035 | CAGR of 9.44%
Category: HealthcareGlobal Peptide-based Cancer Therapeutics Market Size to Exceed USD 71.5 Billion by 2035
According to a Research Report Published by Spherical Insights & Consulting, The Global Peptide-based Cancer Therapeutics Market Size is expected to Grow from USD 26.5 Billion in 2024 to USD 71.5 Billion by 2035, at a CAGR of 9.44% during the forecast period 2025-2035.
Get more details on this report -
Browse 210 Market Data Tables And 45 Figures Spread Through 190 Pages and In-Depth TOC On the "Global Peptide-based Cancer Therapeutics Market Size, Share, and COVID-19 Impact Analysis, By Class (Peptide Hormone Analogues, Peptide-Drug Conjugates, and Vaccines/Others), By Indication (Prostate & Breast, Neuroendocrine/GI, and Melanoma/Others), By Line of Therapy (2L/3L, 1L, and Adjuvant/Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035." Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/peptide-based-cancer-therapeutics-market
The peptide-based cancer therapeutics market is the pharmaceutical industry emphasizing the use of therapeutic peptides for treating cancer. There is an upsurge in the development of therapeutic peptides for a wide range of diseases, especially cancer, preferably used over antibiotics, radiation therapy, and chemotherapy, owing to their flexibility, easy modification, low immunogenicity, and inexpensive production cost. The development of novel therapeutic vaccines by the use of the power of multi-epitope peptides is driving a huge surge in the global market. The growing burden of cancer, along with its increasing mortality rates, attributed to the ageing population, prevalence of unhealthy lifestyles and environmental changes, especially in the low- and middle-income countries, is driving the peptide-based cancer therapeutics market. Furthermore, the technological advancements, including genetic engineering and innovative drug delivery systems, are propelling the market growth. On the contrary, increased development costs, regulatory challenges, and varying patient responses are challenging the peptide-based cancer therapeutics market.
The peptide hormone analogues segment dominated the market with a major share of about 45% in 2024 and is projected to grow at a substantial CAGR during the forecast period.
Based on the class, the peptide-based cancer therapeutics market is divided into peptide hormone analogues, peptide-drug conjugates, and vaccines/others. Among these, the peptide hormone analogues segment dominated the market with a major share of about 45% in 2024 and is projected to grow at a substantial CAGR during the forecast period. Peptide based cancer vaccines present effective clinical data. Further, the emergence of combination therapy with conventional therapies, including radiation and chemotherapy, is propelling the market.
The prostate & breast segment accounted for a significant share of about 39% in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period.
Based on the indication, the peptide-based cancer therapeutics market is divided into prostate & breast, neuroendocrine/GI, and melanoma/others. Among these, the prostate & breast segment accounted for a significant share of about 39% in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. There is increasing focus on peptide-based therapeutic strategies, including cell-penetrating peptides for breast cancer therapy. Further, its role in prostate cancer immunotherapy plays a vital role in prostate cancer treatment.
The 2L/3L segment accounted for the largest market share of about 52% in 2024 and is anticipated to grow at a significant CAGR during the forecast period.
Based on the line of therapy, the peptide-based cancer therapeutics market is divided into 2L/3L, 1L, and adjuvant/others. Among these, the 2L/3L segment accounted for the largest market share of about 52% in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Peptide-based drugs are used in targeted therapy as, alternative to conventional chemotherapy. For instance, the 6MHP vaccine that contains 6 melanoma-associated peptides to stimulate helper T cells, used in combination with pembrolizumab.
North America is expected to hold the majority share of the global Peptide-based Cancer Therapeutics market during the forecast period.
Get more details on this report -
North America is expected to hold the majority share of about 40-50% in the global Peptide-based Cancer Therapeutics market during the forecast period. The United States is dominating the North America peptide based cancer therapeutics market, accounting for nearly 82.1% share in 2024, driven by the advancement in peptide based drug development and the development of peptide-based vesicles for cancer immunotherapy. Advancements in peptide discovery and drug design, with the rise in personalized medicine & precision therapeutics in oncology, are propelling the peptide-based cancer therapeutics market. Further, the expanding biopharma innovation hubs and R&D efforts are bolstering the market growth.
Asia Pacific is anticipated to grow at the fastest pace of CAGR 6.20% in the global Peptide-based Cancer Therapeutics market during the forecast period. China is accounting for the dominant share of about 20-30% in the Asia Pacific peptide based cancer therapeutics market, owing to the expanding biopharma manufacturing, R&D efforts, and government support for peptide based drug development. Significant investment in R&D by the pharmaceutical industries, along with the region’s booming peptide production business, is anticipated to promote the market growth of peptide-based cancer therapeutics.
Major vendors in the global Peptide-based Cancer Therapeutics market are Novartis AG, Ipsen SA, AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bristol Myers Squibb Company (BMS), Takeda Pharmaceutical Company Limited, Merck & Co. Inc., Roche Holding AG, Eli Lilly and Company, and Others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Key Market Development
- In October 2025, Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer, announced preliminary clinical and preclinical findings across its Helicon peptide pipeline at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts.
- In April 2025, the WILEY Online Library published a review article on Peptide-Based Strategies in PLGA-enhanced tumor therapy.
Market Segment
This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Peptide-based Cancer Therapeutics market based on the below-mentioned segments:
Global Peptide-based Cancer Therapeutics Market, By Class
- Peptide Hormone Analogues
- Peptide-Drug Conjugates
- Vaccines/Others
Global Peptide-based Cancer Therapeutics Market, By Indication
- Prostate & Breast
- Neuroendocrine/GI
- Melanoma/Others
Global Peptide-based Cancer Therapeutics Market, By Line of Therapy
- 2L/3L
- 1L
- Adjuvant/Others
Global Peptide-based Cancer Therapeutics Market, By Regional Analysis
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?